Knowledge Base

Which espects should be mentioned when recording a AE? And what should the investigator do if the AE is serious?

8 December 2023
2 min read

When recording an adverse event (AE), it's important to include the following aspects:

Type of AE: This refers to any unfavorable and unintended sign (including abnormal laboratory findings not meeting the criteria for an AE) that occurs during or after treatment with the test article.
Onset: The date and time at which the AE occurred.
Severity: The severity of the AE, ranging from mild to severe.
Outcome: Whether the AE was resolved, ongoing, or resulted in death.
Relationship to study product: Whether the AE was related to the test article or not.
Action taken: Any actions taken by the investigator to address the AE, such as administering medication or providing supportive care.

If an AE is serious, defined as one that results in any of the following outcomes:

Death
Life-threatening events
Inpatient hospitalization or prolongation of existing hospitalization
Persistent or significant disability/incapacity
Conception
Birth defects
Other medically important condition The investigator should take appropriate action to address the AE, including informing the sponsor and institutional review board (IRB) immediately. They may also need to stop further dosing of the study drug until the cause of the AE has been determined and appropriate action has been taken.

What are IDH1 inhibitors and how do you quickly get the latest development progress?
What are IDH1 inhibitors and how do you quickly get the latest development progress?
8 December 2023
IDH1 inhibitors have made great progress in the treatment of acute myeloid leukemia and glioma, but further research is needed to confirm their clinical efficacy in other tumors.
Read →
How to choose a radiolabeled molecule for a radiodiagnostic drug?
Knowledge Base
2 min read
How to choose a radiolabeled molecule for a radiodiagnostic drug?
8 December 2023
The choice of a radiolabeled molecule for a radiopharmaceutical drug depends on several factors, including the target tissue or organ, the specific disease being studied, and the desired properties of the radiotracer.
Read →
Tectonic Therapeutic has initiated its premier clinical scheme for a biologic aimed at GPCR receptors
Latest Hotspot
3 min read
Tectonic Therapeutic has initiated its premier clinical scheme for a biologic aimed at GPCR receptors
8 December 2023
Tectonic Therapeutics, known for GPCR-targeted therapies, has successfully dosed the first cohort in human trials for its Fc-relaxin RXFP1 receptor project.
Read →
What is the difference between a generic drug and an innovator drug?
"What" Series
2 min read
What is the difference between a generic drug and an innovator drug?
8 December 2023
Generic drugs are medications that have been approved by the FDA as equivalent to brand-name drugs in terms of safety, efficacy, and quality.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.